159 related articles for article (PubMed ID: 35015127)
1. Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements.
Hottat NA; Badr DA; Lecomte S; Besse-Hammer T; Jani JC; Cannie MM
Eur Radiol; 2022 Jun; 32(6):4067-4078. PubMed ID: 35015127
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
[TBL] [Abstract][Full Text] [Related]
3. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
[TBL] [Abstract][Full Text] [Related]
4. Assessment of diffusion-weighted MRI in predicting response to neoadjuvant chemotherapy in breast cancer patients.
Hottat NA; Badr DA; Lecomte S; Besse-Hammer T; Jani JC; Cannie MM
Sci Rep; 2023 Jan; 13(1):614. PubMed ID: 36635514
[TBL] [Abstract][Full Text] [Related]
5. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
[TBL] [Abstract][Full Text] [Related]
6. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer.
Liang X; Chen X; Yang Z; Liao Y; Wang M; Li Y; Fan W; Dai Z; Zhang Y
BMC Cancer; 2022 Dec; 22(1):1250. PubMed ID: 36460972
[TBL] [Abstract][Full Text] [Related]
7. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.
Xu HD; Zhang YQ
Neoplasma; 2017; 64(3):430-436. PubMed ID: 28253722
[TBL] [Abstract][Full Text] [Related]
9. Diffusion-weighted MR imaging of locally advanced breast carcinoma: the optimal time window of predicting the early response to neoadjuvant chemotherapy.
Yuan L; Li JJ; Li CQ; Yan CG; Cheng ZL; Wu YK; Hao P; Lin BQ; Xu YK
Cancer Imaging; 2018 Oct; 18(1):38. PubMed ID: 30373679
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of ADC Difference Value on Pre-neoadjuvant Chemotherapy MRI for Response Evaluation of Breast Cancer.
Choi BB
Technol Cancer Res Treat; 2021; 20():15330338211039129. PubMed ID: 34519583
[No Abstract] [Full Text] [Related]
11. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer.
Ahmed SA; Taher MGA; Ali WA; Ebrahem MAES
Abdom Radiol (NY); 2021 Jun; 46(6):2712-2721. PubMed ID: 33547919
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted MRI for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: evaluation with mono-, bi-, and stretched-exponential models.
Suo S; Yin Y; Geng X; Zhang D; Hua J; Cheng F; Chen J; Zhuang Z; Cao M; Xu J
J Transl Med; 2021 Jun; 19(1):236. PubMed ID: 34078388
[TBL] [Abstract][Full Text] [Related]
14. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.
Shin HJ; Baek HM; Ahn JH; Baek S; Kim H; Cha JH; Kim HH
NMR Biomed; 2012 Dec; 25(12):1349-59. PubMed ID: 22566277
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pretreatment ADC values as predictors of treatment response to neoadjuvant chemotherapy in patients with breast cancer - a multicenter study.
Surov A; Pech M; Meyer HJ; Bitencourt AGV; Fujimoto H; Baxter GC; Santamaría G; Gilbert FJ; Wienke A
Cancer Imaging; 2022 Dec; 22(1):68. PubMed ID: 36494872
[TBL] [Abstract][Full Text] [Related]
16. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
[TBL] [Abstract][Full Text] [Related]
17. Using the apparent diffusion coefficient histogram analysis to predict response to neoadjuvant chemotherapy in patients with breast cancer: comparison among three region of interest selection methods.
Geng X; Zhang D; Suo S; Chen J; Cheng F; Zhang K; Zhang Q; Li L; Lu Y; Hua J; Zhuang Z
Ann Transl Med; 2022 Mar; 10(6):323. PubMed ID: 35433990
[TBL] [Abstract][Full Text] [Related]
18. Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer.
Ramírez-Galván YA; Cardona-Huerta S; Elizondo-Riojas G; Álvarez-Villalobos NA
Acad Radiol; 2018 Feb; 25(2):179-187. PubMed ID: 29033147
[TBL] [Abstract][Full Text] [Related]
19. Intravoxel incoherent motion diffusion-weighted MRI for predicting response to neoadjuvant chemotherapy in breast cancer.
Kim Y; Kim SH; Lee HW; Song BJ; Kang BJ; Lee A; Nam Y
Magn Reson Imaging; 2018 May; 48():27-33. PubMed ID: 29278762
[TBL] [Abstract][Full Text] [Related]
20. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
Partridge SC; Zhang Z; Newitt DC; Gibbs JE; Chenevert TL; Rosen MA; Bolan PJ; Marques HS; Romanoff J; Cimino L; Joe BN; Umphrey HR; Ojeda-Fournier H; Dogan B; Oh K; Abe H; Drukteinis JS; Esserman LJ; Hylton NM;
Radiology; 2018 Dec; 289(3):618-627. PubMed ID: 30179110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
